Vir Biotechnology and GSK start phase 2/3 study of COVID-19 antibody treatment
For media and investors only
Issued: San Francisco and London- Phase 2/3 COMET-ICE study will investigate the safety and efficacy of antibody treatment in preventing hospitalisation due to COVID-19
- Potential for initial study results to be available before the end of 2020, with early access to the antibody treatment as soon as the first half of 2021